Abbott Licenses Prostate Cancer Biomarkers for MDx Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today said that it has licensed exclusive rights from Stanford University to several biomarkers that it intends to use in developing a molecular diagnostics test.

Abbott said that it intends to develop a test that can differentiate aggressive from nonaggressive prostate cancer, a currently unmet medical need.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.